Despite the high FLT3 inhibitory efficacy reported in in vitro studies, second-generation FLT3i, Gilteritinib, Quizartinib and Crenolanib showed primary and secondary resistance in FLT3mut AML treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.